Sentences with phrase «metastatic tumor tissue»

To illuminate the process, the Yale team sequenced normal, primary, and metastatic tumor tissue from multiple individuals, including subjects with a range of cancer types.

Not exact matches

They discovered that YAP1 is present at higher levels and interacts with OCT4 more in primary and metastatic lung tumors than normal tissue.

McDonald and close collaborators from Memorial Sloan Kettering Cancer Center and Johns Hopkins University School of Medicine sought to understand how pancreatic cancer progresses from a primary tumor in the pancreas to metastatic disease in distant tissues.

Metastatic cancer cells have the ability to break free from tissue, circulate in the blood stream, and form tumors all over the body, in a way acting like blood cells.

The Ogretmen laboratory screened previously reported microarray data sets of several human tumor tissues (metastatic head and neck squamous cell carcinoma, melanoma, and renal cell carcinoma) and showed that, in these samples, only the levels of CerS4 were significantly decreased.

The team chose to compare breast tissue from healthy individuals with tumor samples taken from breast cancer patients — including both primary tumors that had not spread from the breast to other body sites, and highly aggressive, metastatic tumors.

They then compared the pattern of gene abnormalities in the initial myeloma tissue and the metastatic tumors.

The biopsy of his primary tumor pointed to treatment with anti-HER2 therapy (Herceptin), but tissue from the metastatic biopsy, as well as cfDNA analysis, was negative for HER2 and positive for anti-epidermal growth factor receptor (EGFR) therapy (ABT - 806).

Furthermore, we examined the expression of KLF4 in brain metastatic tissues by immunohistochemistry and found that KLF4 was expressed more in the nucleus and significantly less in cytosol in brain metastatic tissues compared with primary tumors (Fig. 6C and D).

To further validate the clinical significance of miR - 7 and KLF4 in brain metastasis of breast cancer, we microdissected tumor tissues from both primary and brain metastatic lesions followed by conducting TaqMan qRT - PCR.

We found that the expression of miR - 7 was significantly lower in brain metastatic tumors than that in primary tumor tissues (Fig. 6A, left), whereas the expression of KLF4 was significantly higher in brain metastatic tissue compared with primary tumors (Fig. 6A, right).

For more information regarding Bristol - Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: • Early stage IB - IIIA, operable non-small cell lung cancer, confirmed in tissue • Lung function capacity capable of tolerating the proposed lung surgery • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 - 1 • Available tissue of primary lung tumor Exclusion Criteria: • Presence of locally advanced, inoperable or metastatic disease • Participants with active, known or suspected autoimmune disease • Prior treatment with any drug that targets T cell co-stimulations pathways (such as checkpoint inhibitors) Other protocol defined inclusion / exclusion criteria could apply

Inclusion Criteria: • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 • Have histologically or cytologically confirmed advanced or metastatic non-small cell lung cancer (NSCLC)(Stage IIIb or greater) • Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 • Known PD - L1 tumor status as determined by an immunohistochemistry (IHC) assay performed by the central laboratory on tissue obtained at Screening • A woman of childbearing potential must have a negative highly sensitive serum (beta - human chorionic gonadotropin [beta - hCG]-RRB- at Screening within 14 days prior to study drug administration Inclusion Criteria for Crossover: • Participants must have been randomized to Arm A of the study and had radiographic disease progression according to RECIST 1.1 • Participants must have a mandatory biopsy at the time of disease progression according to RECIST 1.1 prior to crossing over.

The researchers took healthy tissue and tumor samples from mice, and trained the nanoparticle - GFP sensors to recognize the bad cells, and for the GFP to fluoresce in the presence of metastatic tissues.

Tissue heterogeneity in PD - L1 expression in both primary and metastatic sites indicates that a single core biopsy might not be sufficient to determine tumor PD - L1 expression.

For AQUA analysis, 2 pairs of slides (containing two cores from different areas of each matching primary and metastatic tumor per patient) or test arrays of cores from FFPE placental tissue and MEL624 cells not overexpressing or overexpressing PD - L1 were concomitantly stained.

Identification of genes associated with local aggressiveness and metastatic behavior in soft tissue tumors.

[25] Seeing that in metastatic patients the only available tumor is often core biopsies rather than whole tissue blocks, we next attempted to determine whether the degree of heterogeneity varies between primary and metastatic sites, using the TMA cores as surrogates for core biopsy specimens.

Inclusion Criteria: • Availability of tumor tissue for mesothelin expression testing • Histologically - confirmed, mesothelin - expressing metastatic or advanced non-metastatic disease (tumour type specific inclusion criteria) • At least one measurable lesion according to either Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or International Thymic Malignancy Interest Group (ITMIG) modified RECIST 1.1 as applicable • Adequate bone marrow, liver, renal and coagulation function • Left ventricular ejection fraction (LVEF) ≥ 50 % of the lower limit of normal (LLN) according to local institutional ranges • Eastern Cooperative Oncology Group (ECOG) 0 or 1 Exclusion Criteria: • More than one prior anti - tubulin / microtubule agent • Corneal epitheliopathy or any eye disorder that may predispose the patients to this condition • Symptomatic Central nervous system (CNS) metastases and / or carcinomatous meningitis • Contraindication to both CT and MRI contrast agents • Active hepatitis B or C infection • Pregnant or breast - feeding patients • Tumor type specific exclusion critumor tissue for mesothelin expression testing • Histologically - confirmed, mesothelin - expressing metastatic or advanced non-metastatic disease (tumour type specific inclusion criteria) • At least one measurable lesion according to either Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or International Thymic Malignancy Interest Group (ITMIG) modified RECIST 1.1 as applicable • Adequate bone marrow, liver, renal and coagulation function • Left ventricular ejection fraction (LVEF) ≥ 50 % of the lower limit of normal (LLN) according to local institutional ranges • Eastern Cooperative Oncology Group (ECOG) 0 or 1 Exclusion Criteria: • More than one prior anti - tubulin / microtubule agent • Corneal epitheliopathy or any eye disorder that may predispose the patients to this condition • Symptomatic Central nervous system (CNS) metastases and / or carcinomatous meningitis • Contraindication to both CT and MRI contrast agents • Active hepatitis B or C infection • Pregnant or breast - feeding patients • Tumor type specific exclusion criTumor type specific exclusion criteria

Sometimes, after examining tumor tissue, the tumor is diagnosed as a metastatic brain tumor but the patient has no history of cancer.

Synovial sarcoma is a cancer in the joints with a five - year and ten - year survival for people with Grade 3 tumors or metastatic disease of less than 25 % and 15 %, respectively, and Myxoid round cell liposarcoma is a malignant tumor that most often occurs in the deep - seated soft tissues of the extremities.

Inflammatory carcinoma is an especially aggressive form that has a high metastatic index (tendency to spread to other tissues), carrying the most poor prognosis of all mammary tumors.